Free Trial

TriSalus Life Sciences (TLSI) Stock Price, News & Analysis

TriSalus Life Sciences logo
$4.89 -0.11 (-2.20%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$4.88 0.00 (-0.10%)
As of 07/11/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About TriSalus Life Sciences Stock (NASDAQ:TLSI)

Key Stats

Today's Range
$4.88
$5.03
50-Day Range
$4.89
$5.59
52-Week Range
$3.50
$6.04
Volume
27,428 shs
Average Volume
52,062 shs
Market Capitalization
$185.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.75
Consensus Rating
Buy

Company Overview

TriSalus Life Sciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
60th Percentile Overall Score

TLSI MarketRank™: 

TriSalus Life Sciences scored higher than 60% of companies evaluated by MarketBeat, and ranked 603rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    TriSalus Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    TriSalus Life Sciences has received no research coverage in the past 90 days.

  • Read more about TriSalus Life Sciences' stock forecast and price target.
  • Earnings Growth

    Earnings for TriSalus Life Sciences are expected to grow in the coming year, from ($1.55) to ($0.61) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of TriSalus Life Sciences is -4.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of TriSalus Life Sciences is -4.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about TriSalus Life Sciences' valuation and earnings.
  • Percentage of Shares Shorted

    3.46% of the float of TriSalus Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    TriSalus Life Sciences has a short interest ratio ("days to cover") of 7.3.
  • Change versus previous month

    Short interest in TriSalus Life Sciences has recently increased by 359.82%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    TriSalus Life Sciences does not currently pay a dividend.

  • Dividend Growth

    TriSalus Life Sciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.46% of the float of TriSalus Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    TriSalus Life Sciences has a short interest ratio ("days to cover") of 7.3.
  • Change versus previous month

    Short interest in TriSalus Life Sciences has recently increased by 359.82%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    TriSalus Life Sciences has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.00 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for TriSalus Life Sciences this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for TLSI on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 1 people have added TriSalus Life Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, TriSalus Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $83,528.00 in company stock.

  • Percentage Held by Insiders

    27.50% of the stock of TriSalus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 2.58% of the stock of TriSalus Life Sciences is held by institutions.

  • Read more about TriSalus Life Sciences' insider trading history.
Receive TLSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TriSalus Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

TLSI Stock News Headlines

Trump’s whole-government AI plans leaked
The New Elon Musk is officially stepping back from his day-to-day duties with DOGE. At least, that's the story the mainstream media will tell you. The reality is very different. See, Elon and the president have been planning for this moment since January. They've even lined up a replacement (a billionaire connection of Elon's) to bring the DOGE operation to its final, logical conclusion. It's going to reset how our government works in a permanent, irreversible way... And it could have a major impact on how you collect Social Security, pay your taxes, and collect benefits from the US government.
See More Headlines

TLSI Stock Analysis - Frequently Asked Questions

TriSalus Life Sciences' stock was trading at $5.01 at the beginning of the year. Since then, TLSI shares have decreased by 2.4% and is now trading at $4.89.

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) issued its earnings results on Thursday, May, 15th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.13. The business earned $9.17 million during the quarter, compared to the consensus estimate of $9.04 million.
Read the conference call transcript
.

Shares of TLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that TriSalus Life Sciences investors own include AutoZone (AZO), Intel (INTC), Meta Platforms (META), Merck & Co., Inc. (MRK), TJX Companies (TJX), Abacus Health Products (ABAHF) and Airbnb (ABNB).

Company Calendar

Last Earnings
5/15/2025
Today
7/11/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:TLSI
Previous Symbol
NASDAQ:TLSI
CIK
1826667
Fax
N/A
Employees
106
Year Founded
N/A

Price Target and Rating

High Price Target
$12.50
Low Price Target
$10.00
Potential Upside/Downside
+119.8%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.12)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$30.05 million
Net Margins
-84.67%
Pretax Margin
-84.65%
Return on Equity
N/A
Return on Assets
-111.63%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.14
Quick Ratio
1.78

Sales & Book Value

Annual Sales
$29.43 million
Price / Sales
6.29
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.83) per share
Price / Book
-5.89

Miscellaneous

Outstanding Shares
37,840,000
Free Float
27,433,000
Market Cap
$185.04 million
Optionable
Not Optionable
Beta
0.50
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:TLSI) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners